4 results
To characterize safety, tolerability, pharmacodynamic effects, and pharmacokinetics of the oral sGC stimulator BAY 1021189 in addition to standard therapy for heart failure with reduced EF (HFrEF) over 12 weeks in patients with worsening chronic…
The objective of this research is to see if this way of treating a patient ensures a quicker diagnosis, which results in lessabdominal pain for the patient.
Primary:- to characterize the metabolic profile of dalcetrapib and identify circulating and excreted metabolitesSecundary:- to explore the influence of drug metabolizing enzyme and drug transporter genotype on the metabolic profile of dalcetrapib.-…
The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction (MI) and non-fatal stroke) in…